Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Oncology Office Hopes Better Advice Will Lead To More Patient-Reported Outcomes Data

Executive Summary

Office of Hematology and Oncology Products now has PRO leads in each clinical review division and is working more collaboratively with, rather than parallel to, the agency’s Study Endpoints and Labeling Development team to give sponsors consistent advice on use of PRO measures in trials.

You may also be interested in...



Oncology Patient-Reported Outcomes Tool May Lead To Comparative Tolerability Claims

New trial designs would be needed to support labeling claim using National Cancer Institute's PRO-CTCAE instrument.

FDA REMS Reforms Lacking Patient Engagement So Far

As new repository website launches, agency acknowledges that it must do more to create patient-focused risk management.

Breast Cancer Patients, FDA Disagree On Value Of Time-To-Metastasis Endpoints

FDA doesn’t seem ready to support clinical trial endpoint asked for by metastatic breast cancer patients at patient-focused drug development meeting.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS056779

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel